Skip to main content
Clinical Trials/NCT02732106
NCT02732106UnknownNot Applicable

Characterization of Adipose Derived Regenerative Cells (ADRCs) From Excess Tissue and Cells Designated for Discard From Patients With Chronic Heart Disease

Cytori Therapeutics4 sites in 1 country20 target enrollmentStarted: April 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
20
Locations
4
Primary Endpoint
Adipose-Derived Regenerative Cells (ADRCs)- Cell Characterization

Study Overview

Brief Summary

Human adipose tissue is now recognized as an acceptable, highly abundant source of adipose-derived regenerative cells (ADRCs). ADRCs are a heterogeneous or mixed population of cells found in adipose tissue including adult stem cells, leukocytes, connective tissue and vessel-associated cells. Autologous adult regenerative cells are thought to promote healing of scarred or injured tissue. While the investigators are learning more about the exact mechanisms every day, it is believed that this heterogeneous population of cells influences the local environment via cell-to-cell signaling, immune modulation, and differentiation into other cell types. The use of ADRCs in the treatment of many different medical conditions (including cardiovascular disease, soft tissue defects, wound healing, and many more) is being evaluated in numerous clinical and preclinical studies around the world. While there is a considerable amount of information regarding the cellular composition of ADRCs isolated from healthy donors, basically there is no much data regarding the ADRC composition from cardiac patients. In this study, adipose tissue or cells from chronic heart ischemia patients, that would otherwise be thrown away in waste, will be provided to researchers who will study these cells with the objective to characterize ADRCs derived from patients with a heart disease and to compare if a heart disease state does impact ADRC cell composition.

Study Design

Study Type
Observational
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients enrolled in the ATHENA clinical trial that donated their leftover material to be studied.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Adipose-Derived Regenerative Cells (ADRCs)- Cell Characterization

Time Frame: Day 1

Cells will be evaluated regarding cell composition by flow cytometric assays.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Cytori Therapeutics
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials

Completed
Not Applicable
Factors That Influence Adipose Derived Regenerative Cells' Yield and ViabilityProblem of AgingSmokingPhysical ActivityGender
NCT02651233Clinical Centre of Serbia46
Unknown
Phase 1
Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb IschemiaCritical Limb IschemiaThromboangiitis ObliteransDiabetic AngiopathiesPeripheral Arterial DiseaseArteriosclerosis Obliterans
NCT02864654Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation9
Completed
Not Applicable
clinical results of adipose-derived regenerative cell therapy for osteoarthritisosteoarthritis
JPRN-UMIN000033510Kanazawa University50
Active, not recruiting
Not Applicable
A clinical evaluation of adipose derived Regenerative cells in the treatment of patients with brEast deformities post Segmental breast resection (lumpectomy) with Or without Radiation therapy. A phase IV post market study – the RESTORE 2 trialEvaluación clínica de células regenerativas derivadas de tejido adiposo para el tratamiento de pacientes con deformidades mamarias tras mastectomia segmentaria (cuadrantectomia) con o sin radioterapia. Un ensayo fase IV de farmacovigilancia – Ensayo RESTORE -2 - RESTORE-2Pacientes con deformidades mamarias tras mastectomía segmentaria (cuadrantectomía) con o sin radioterapia
EUCTR2007-007956-33-ESCytori Therapeutics Inc70
Completed
Not Applicable
Fat Grafts With Adipose-derived Regenerative Cells for Soft Tissue Reconstruction in ChildrenCraniofacial Microsomia
NCT03806361Hospital Sirio-Libanes30
Characterization of Adipose Derived... | Clinical Trial